In accordance with ACR guidelines, allopurinol is strongly proposed as a primary-line urate-reducing medication. Genetic screening is suggested (to get a variant identified as HLA B*5801) just before starting allopurinol since the carriers of the gene are at a heightened chance of the significant allergic response.Anda boleh mendapatkan beberapa NS